Yunji

Yunji rose 9.56% in regular trading, climbing from its open of $1.360 to a high of $1.490, driven by its fiscal 2025 results showing a significant narrowing of net loss and the market's positive reception to its pivot to private-label health products. Net loss for FY2025 shrank approximately 80% YoY, with EPS of -$0.5717 improving 75.85%, though revenue still declined 14.77% YoY. The current price of $1.49 remains below the 60-day MA of $1.598 and is 44.19% off its 52-week high of $2.67; however, it is up 25.21% YTD and trades at a PB of 0.05x. The stock gave back some gains in after-hours trading, settling at $1.40.

Yunji (YJ.US) traded lower during regular hours on Wednesday, falling approximately 5.6% to $1.360 as of 11:19 ET, driven by ongoing revenue contraction revealed in its recently released FY2025 annual report. The company reported Q4 2025 operating revenue of $11.34 million, down 14.77% year-over-year, and a net loss of $2.33 million, which narrowed by 80.02% compared to the prior year, though the net profit margin remained deeply negative at -20.53%. Year-to-date the stock is up 14.29%, but the current price sits 49.06% below its 52-week high of $2.67 and has fallen below both the 20-day MA ($1.433) and 60-day MA ($1.604), signaling technical weakness. However, pre-market saw no actual trades, and regular session volume was low at just 1,689 shares.

Yunji (YJ.US) opened sharply lower in regular trading, last at $1.440 as of ET 10:00, down 4.0% from the prior close of $1.500, as the stock surged to an intraday high of $2.080 in pre-market before collapsing, with only 380 shares traded in the regular session, highlighting extreme illiquidity. FY2025 revenue fell 14.77% YoY to $11.34M, but net loss narrowed 80.02% to $2.33M, with EPS of -$0.5717 vs -$2.36 a year ago, showing significant margin improvement. Despite a 21.01% YTD gain, the stock trades 10.9% below its 60-day MA of $1.617 and 46.07% below the 52-week high of $2.67. The pre-market spike appears to be speculative, with liquidity drying up during regular hours, though continued loss reduction and the pivot to private-label health products may offer a long-term anchor.

Yunji hit an intraday high of $1.49 but closed at $1.425, up 7.14% from the prior close of $1.33, though gains were capped below the pre-market peak of 9.77%. The gap-up opening was driven by broad sector momentum in consumer discretionary stocks during Thursday's pre-market session, but upward momentum faded. The company's 2025 net loss narrowed sharply by 80.02% to a loss per share of $0.5717, while revenue declined 14.77% YoY to $11.34 million, showing fundamental improvement insufficient to sustain a rally. The stock remains 46.63% below its 52-week high of $2.67 and trades below both the 20-day MA ($1.454) and 60-day MA ($1.635), indicating a weak technical posture. However, the stock has gained 19.75% year-to-date, rebounding 28.38% from its 52-week low of $1.11, reflecting the market's recognition of narrowing losses.

YJ.US 今日盘中单边下挫，收盘报 1.339 美元，较前收盘 1.450 美元下跌 7.66%，主因是公司 2025 年下半年财报显示营收持续萎缩且亏损依旧。财报显示，2025 年 Q4 营收 1134 万美元，同比下滑 14.77%，Q3 营收 1114 万美元，同比减少 9.87%；Q4 净亏损 232.8 万美元，虽较上年同期亏损收窄 80.02%，但净利率仍为-20.53%。从盘中走势看，盘前交易价维持在 1.450-1.460 美元，开盘后即快速走低，盘中最低触及 1.339 美元，形成单边下行走势。当前股价已跌破盘前价格区间，距日内高点 1.460 美元下跌 8.29%，总市值仅约 660 万美元，市净率 0.05 倍，低于净资产。近期资讯中，公司刚于 3 月 27 日发布 2025 年全年业绩，市场消化后持续承压，盘后交易价进一步跌至 1.390 美元。